Lipid Market

Key data points: Market size in 2027 = $16 billion and 2035 = $39 billion, growth forecast = 9.5% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in lipid market to 2035 by product type (omega-3 & omega-6, medium-chain triglycerides, phospholipids, and others), source (plant-based, marine-based, animal-based, and synthetics), form (liquid, powder, and others), application (dietary supplements, food & beverage, animal feed, pharmaceuticals, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Lipid Market The future of the global lipid market looks promising with opportunities in the dietary supplement, food & beverage, animal feed, and pharmaceutical markets. The global lipid market is expected to reach an estimated $39 billion by 2035 from $16 billion in 2027 with a CAGR of 9.5% from 2027 to 2035. The major drivers for this market are the increasing demand for functional food ingredients, the rising use of lipids in nutraceuticals, and the growing adoption of plant based oils. • Lucintel forecasts that, within the product type category, omega-3 & omega-6 will remain the largest segment over the forecast period due to the growing demand for essential fatty acid nutritional supplements. • Within the application category, pharmaceutical is expected to witness the highest growth over the forecast period due to increasing pharmaceutical applications of omega fatty acids. • In terms of regions, Europe will remain the largest region over the forecast period due to the strong nutraceutical market and rising health awareness. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Lipid Market Designers predict rapid growth of the lipid nanoparticle (LNP) technology sector beyond the bounds of its original use case of mRNA-based vaccines over the next few years. According to the Lucintel report, delivery platform innovation and widening application diversity will differentiate industry leaders from single-use vaccine suppliers in the future. • LNP Technology Going Beyond Vaccines: Beyond its original use case, mRNA vaccines, lipid nanoparticle technologies are being researched for oncology, regenerative medicine, and neurology. Given the expanding research of LNP-delivered therapies for rare genetic disorders and chronic disease treatment, this technology will continue to bring opportunities to market segments beyond infectious diseases. • Ionizable Lipid Engineering: Research is underway to develop the next generation of lipids to improve biodegradability, endosomal escape, and protein expression levels. Recent studies have achieved protein expression levels 3-5 times greater than first generation lipids. This research will transform mRNA therapies for a wide range of disorders and diseases. • LNP Targeting Technology: With the goal of eliminating systemic off-target effects, cell targeting ligands are being developed to bind lipid nanoparticles to specific cells. A liver-targeted lipid nanoparticle delivery system has been proven to have 90% efficiency in pre-clinical models. • CDMO Outsourcing: Growth in lipid nanoparticle (LNP) manufacturing has LNP contract development and manufacturing organizations (CDMOs) being the first choice as most pharmaceutical companies outsource this service. WACKER and CordenPharma's partnership in 2024 is a prime example of this phenomenon. Outsourcing will continue to gain traction because biopharma companies focus on their core competencies of therapy development with complex manufacture- ing requiring high capital expenditures." • AI-Assisted Formulation Design: Researchers combine artificial intelligence and computational modeling to design nanoparticles, simplifying the development process and allowing for advancements in precision delivery mechanism. This integration will continue to shorten development timelines as computational tools become available and the industry relies less on traditional formulation methods. Lipid nanoparticles are becoming a primary delivery system in different drug formulations; they are not just for vaccine formulations. Companies using AI to design systems with targeting precision will outpace those using first generation formulation systems. Recent Developments in the Lipid Market The lipid nanoparticle market was bustling from 2024 to 2026 as pharmaceutical companies rushed to produce both in-house and outsourced capacity to meet the demand of the growing RNA therapeutics pipeline. According to Lucintel, domestic manufacturing capacity is now reshaping competition at magnitude comparable to technology partnerships. • Major Domestic Manufacturing Investment: Moderna announced in November 2025 a manufacturing investment of more than $140 million to add more mRNA manufacturing stages to its Norwood, Massachusetts facility. This investment increases Moderna's domestic manufacturing readiness and lessens its dependence on contract manufacturing organizations (CMOs) for core manufacturing. • Collaboration: WACKER and CordenPharma signed a collaboration agreement on lipid nanoparticle formulation in 2024. Both companies aim to jointly develop the lipid nanoparticle formulation capability to meet the market demand for lipid nanoparticles. Partnership like this allows established chemical and pharmaceutical manufacturing companies the opportunity to develop lipid nanoparticle formulations as a collaborative effort, rather than developing it as a completely standalone effort. • Market Entrant: Aurora Biosynthetic, based in Asia Pacific, launched in September 2024 offering end to end GMP manufacturing of plasmid DNA, mRNA, and lipid nanoparticles. This shows that Asia Pacific is moving from the research stage of RNA therapeutics to the real stage of commercial manufacturing. • Manufacturing Support: Continued government support for Evonik by BARDA demonstrates government interest to provide manufacturing capability for RNA therapeutics in the U.S. For government funding to be at this level also demonstrates that lipid nanoparticle capacity has moved from a commercial to a strategic national infrastructure. • Supply Agreement Expansion: VAV Lifesciences has entered a contract with a CDMO to supply them with the nanoparticles needed for vaccine manufacturing. This is the latest example of a growing number of companies in this sector formalizing lipid nanoparticle supply contracts. The industry has clearly identified securing a supply of LNPs as a priority as this segment of the industry focuses on manufacturing vaccines and therapeutics. The rest of the industry has recognized this as a priority. While the rest of the industry is focusing on a priority that is as important as securing LNP supply, the rest of the industry is doing things like domestic manufacturing and corporate partnerships that will ultimately shape this industry. Combining domestic capacities and contracted services, like those done by Moderna and WACKER-CordenPharma, will retain and establish powerful positions in the industry for the next decade. Strategic Growth Opportunities in the Lipid Market The next few years will create new business opportunities related to lipid nanoparticles (LNPs) extending beyond the use of the technology for mRNA vaccines in oncology, gene therapy, and targeted drug delivery from 2024 to 2026. Per the new Lucintel market study, the highest growth is coming from the suppliers who are able to move beyond the use of vaccines. • Oncology and Gene Therapy: The use of LNPs is extending beyond the use of vaccines into the use of cancer treatments and gene editing. As research pipelines are starting to use LNPs to deliver treatments for rare genetic disorders and chronic diseases, new oncology-focused capabilities for formulating LNPs will provide suppliers with opportunities for higher profit potential per treatment compared to what is seen for vaccines. • Targeted Delivery: There is a clear business opportunity for precision-targeted therapy for chronic diseases which require multiple treatments. There has been over 90 percent delivery efficiency of liver-targeted LNPs utilized in pre-clinical studies. There is a clear need for new technologies to create organ specific delivery. • CDMO Services: The partnership between CordenPharma and WACKER in 2024 outlines how the majority of pharmaceutical companies have opted to outsource their LNP manufacturing instead of developing their own manufacturing capability. Depending on biopharmaceutical companies' RNA therapy manufacturing partnerships, suppliers will gain a stable client relationship through the development of complete CDMO services. • Manufacturing Growth in Asia-Pacific: The launch of Aurora Biosynthetic in September 2024 to offer end-to-end GMP manufacturing for mRNA lipid nanoparticles and plasmid DNA in the Asia-Pacific region highlights a clear business opportunity for commercial-scale manufacturing of RNA therapeutics in the region. The first businesses to create a manufacturing infrastructure in the region will have the first-mover advantage before the market matures and the competition increases. • AI-Assisted Formulation Development: Using artificial intelligence and computational modeling to design nanoparticles shortens development time. Starting this process will make you stand out from competition that isn't using artificial intelligence. Diversification of Lipid Nanoparticles is primarily driven by new uses rather than increasing volume of existing formulations. These newly formed partnerships will achieve greater growth potential than companies only involved with legacy, vaccines only, offerings. Lipid Market Drivers and Challenges Increased demand for Lipid nanoparticles results from growth in RNA therapeutics. This growth is challenging suppliers with the need for advanced infrastructure to meet the demand. Lucintel projects that the balance between supply and demand will dictate which suppliers expand most profitably during this period. Key factors • Increased Demand for Therapeutics: Rapidly increasing demand for therapeutics for use in mRNA vaccines, cancer therapeutics, and gene therapies drives demand for delivery systems. It is estimated that the global market for Lipid nanoparticles will be approximately $786.4 million by 2024. The expanding demand for RNA therapeutics is creating an even greater need for therapeutics. • Enhanced Formulation Technology: Researchers are looking at next generation lipids and expect improved stability and endosomal escape. Several researchers have reported protein expression levels that are a minimum of 3 - 5-fold than the initial lipids. Formulation technology is expected to drive increased therapeutic efficacy and extend the therapeutic window for diseases for which mRNA therapeutics can be used. • Domestic Manufacturing: Moderna’s investment in November 2025 of over $140 million to expand its lipid nanoparticle manufacturing plant experienced increased domestic manufacturing. This insured active construction and reduced dependence on CMOs for therapeutic lipid nanoparticle utilization. • Expansion of CDMO Partnerships: There is an increasing reliance on CMOs demonstrated by the partnership between WACKER and CordenPharma for 2024. This partnership is reflective of the overall increase in partnerships with CMOs as pharmaceutical companies look to outsource to reduce the complexities of manufacturing. • Government Funding Support: Public funding, such as BARDA investing in Evonik's lipid nanoparticle manufacturing facility, shows continued government interest in the development of domestic RNA therapeutic manufacturing capacity. The government will likely continue to provide public funding and support the construction of manufacturing infrastructure as states view LNP manufacturing as a strategic capability. Challenges • Manufacturing Scalability Limitations: Producing batches of materials which are consistent and having uniform particles at the commercial scale is technically difficult, and makes it hard to transition production from a clinical to a commercial scale. • High Initial Costs: It is difficult to set up lipid nanoparticle manufacturing facilities to meet the Good Manufacturing Practices (GMP) standard, and this tends to generate a lot of financial burden on small biotech companies and local producers in particular. • Supply Chain: Raw materials that are ionizable lipids, in particular, are sourced from a few suppliers, and therefore, the manufacturing supply chain is vulnerable to shortages. High capital and manufacturing scalability will continue to favor well established players with an infrastructure to carry out manufacturing to GMP standards. Focusing on formulation innovation combined with domestic manufacturing will enable these companies to better secure long term supply contracts with biopharma companies in the next few years. List of Lipid Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies lipid market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lipid market companies profiled in this report include- • BASF SE • DSM-Firmenich • Croda International Plc • Solutex GC, S.L. • Clover Corporation Limited • Kerry Group Plc • Evonik Industries AG • Lonza Group • Cabio Biotech (Wuhan) Co., Ltd. • Stepan Company Lipid Market by Segment The study includes a forecast for the global lipid market by product type, source, form, application, and region. Lipid Market by Product Type [Value ($B) from 2019 to 2035]: • Omega-3 & Omega-6 • Medium-Chain Triglycerides • Phospholipids • Others Lipid Market by Source [Value ($B) from 2019 to 2035]: • Plant-Based • Marine-Based • Animal-Based • Synthetics Lipid Market by Form [Value ($B) from 2019 to 2035]: • Liquid • Powder • Others Lipid Market by Application [Value ($B) from 2019 to 2035]: • Dietary Supplements • Food & Beverage • Animal Feed • Pharmaceuticals • Others Lipid Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Lipid Market Demand for RNA-based therapeutics will drive a surge in interest in the lipid market from 2024 to 2026, greatly increasing the value of the global lipid nanoparticle market from $786.4 million in 2024. As reported by Lucintel, activity in this space will particularly manifest as investments in production capacity and contract development and manufacturing organizations (CDMOs). • The United States: Moderna plans to invest more than $140 million in the expansion of its production facility in the Norwalk, Massachusetts, production facility in November 2025. With the new facility, production of different stages of mRNA will occur at a single site. This expansion of production will strengthen U.S. readiness and reduce the need for external lipid nanoparticle manufacturers. • China: Chinese biotechnology companies attract investments in lipid nanoparticle manufacturing. These companies are positioned in one of the less expensive production sites along the global supply chain for mRNA and RNA therapeutic manufacturing. This investment will allow China to become a competitive lipid nanoparticle manufacturing site in the Asia-Pacific region. • Germany: In 2024, WACKER and CordenPharma will enter a partnership to develop on a scale the production of lipid nanoparticles. This partnership will allow Germany to fulfill the market demand for GMP-compliant lipid nanoparticle production and strengthen the role of Germany in the European lipid nanoparticle CDMO market, valued at $0.08 billion in 2025. • India: The rapidly expanding and cost-competitive lipid nanoparticle manufacturing capacity, coupled with government support for local biologics manufacturing and innovation, has resulted in significant investments in Indian biopharma manufacturing. This has the potential to make India one of the fastest growing lipid nanoparticle manufacturing locations in the Asia-Pacific region, along with China. • Japan: Japanese research institutions and biotechnology companies continue to advance research and development of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and oncology purposes. Supported by the steady investment in biotech collaboration, Japan continues to lead the lipid nanoparticle market in the region. Features of the Global Lipid Market Market Size Estimates: lipid market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: lipid market size by various segments, such as by product type, source, form, application, and region in terms of value ($B). Regional Analysis: lipid market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different product types, sources, forms, applications, and regions for the lipid market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lipid market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the lipid market by product type (omega-3 & omega-6, medium-chain triglycerides, phospholipids, and others), source (plant-based, marine-based, animal-based, and synthetics), form (liquid, powder, and others), application (dietary supplements, food & beverage, animal feed, pharmaceuticals, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 6 years and what has its impact been on the industry?